Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.702,42
0,46%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Akebia Therapeutics Inc (AKBA) Akebia Therapeutics Inc (AKBA) Notizie

Akebia Therapeutics Inc

AKBA
1,3303
0,0003 (0,02%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/4/202422:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
28/3/202401:26PRNUSAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets..
14/3/202421:15PRNUSAkebia Therapeutics Reports Fourth Quarter and Full Year..
11/3/202422:05PRNUSAkebia Therapeutics to Report Fourth Quarter and Full Year..
01/3/202423:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
01/3/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:32EDGAR2Form 144 - Report of proposed sale of securities
29/2/202422:28EDGAR2Form 144 - Report of proposed sale of securities
29/2/202422:27EDGAR2Form 144 - Report of proposed sale of securities
28/2/202400:19EDGAR2Form 144 - Report of proposed sale of securities
28/2/202400:14EDGAR2Form 144 - Report of proposed sale of securities
28/2/202400:11EDGAR2Form 144 - Report of proposed sale of securities
13/2/202414:00EDGAR2Form 8-K - Current report
02/2/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
01/2/202422:52EDGAR2Form 144 - Report of proposed sale of securities
30/1/202422:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/1/202414:05EDGAR2Form 8-K - Current report
30/1/202414:00PRNUSAkebia Secures $55 Million Term Loan Financing
18/1/202423:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202414:30PRNUSAkebia Therapeutics Announces Appointment of Nicholas Grund..
08/1/202422:08EDGAR2Form 8-K - Current report
08/1/202414:02EDGAR2Form 8-K - Current report
02/1/202422:30PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
20/12/202314:00PRNUSAkebia Therapeutics to Present at the 42nd Annual J.P...
18/12/202322:07EDGAR2Form 8-K - Current report
01/12/202322:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
21/11/202323:07EDGAR2Form 8-K - Current report
20/11/202314:00PRNUSAkebia Therapeutics to Present at Piper Sandler Healthcare..
08/11/202313:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:33EDGAR2Form 8-K - Current report
08/11/202313:30PRNUSAkebia Therapeutics Reports Third Quarter 2023 Financial..
02/11/202321:34EDGAR2Form 8-K - Current report
02/11/202321:30PRNUSAkebia Therapeutics Announces Favorable Payment Term..
01/11/202321:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
31/10/202313:00PRNUSAkebia Therapeutics to Report Third Quarter 2023 Financial..
25/10/202322:06EDGAR2Form 8-K - Current report
Apertura: 1,32 Min: 1,29 Max: 1,35
Chiusura: 1,33

La tua Cronologia

NASDAQ
AKBA
Akebia Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network